

PATENT
ATTORNEY DOCKET NO. 50216/003004

11000 U.S. PTO
09/919703
07/31/01

Certificate of Mailing	
Date of Deposit <u>7/31/01</u>	Label Number: <u>EL 834597195 US</u>
I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to: BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231.	
<u>Guy Beardsley</u> Printed name of person mailing correspondence	<u>Guy Beardsley</u> Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Gerald Krystal et al.	Art Unit:	Not yet assigned
Serial No.:	Not yet assigned	Examiner:	Not yet assigned
Filed:	July 31, 2001	Customer No.:	21559
Title:	PEPTIDES AND THEIR USE TO AMELIORATE CELL DEATH		

Assistant Commissioner For Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Applicants submit the attached form PTO-1449.

Submission of this statement is not a representation that a search has been made, nor is information included in this statement an admission that the information is material to patentability.

Under 35 U.S.C. § 120, this application relies on the earlier filing date of application serial number 09/294,457, filed on April 19, 1999. All of the cited references were submitted to and/or cited by the Office in the prior application and, therefore, is not provided in this application.


If there are any other charges, or any credits, please apply them to Deposit

Account No. 03-2095.

Respectfully submitted,

Date:

July 31, 2001



Kristina Bieker-Brady, Ph.D.
Reg. No. 39,109

Paul T. Clark
30,162

Clark & Elbing LLP
176 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

\\Clark-w2k1\documents\50216\50216.003004 Information Disclosure Statement.wpd



21559

PATENT TRADEMARK OFFICE

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

(37 C.F.R. §1.98(b))

Attorney Docket No.

50216/003004

Serial No.

Not yet assigned

Applicant

Gerald Krystal et al.

Filing Date

Not yet assigned

Group

Not yet assigned

IDS Filed

July 31, 2001

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
	5,917,013	06/29/99	Rabkin et al.	530	300	

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 94/07992	04/14/94	PCT			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

	Fung et al., "Beneficial Effects of Streptokinase on Left Ventricular Function After Myocardial Reoxygenation and Reperfusion Following Global Ischemia in the Isolated Rabbit Heart," <i>J. Cardiovasc. Pharmacol.</i> 6(3):429-435, 1984.
	Jackson and Tang, "Complete Amino Acid Sequence of Streptokinase and Its Homology with Serine Protease," <i>Biochemistry</i> 21: 6620-6625, 1982.
	Krul, <i>Spectrum: Therapy Markets and Emerging Technologies</i> , Decision Resources, Inc., Waltham, Massachusetts, August 18, 1994, "Apoptosis: A New Therapeutic Approach to Cell-Based Disorders."
	Mickelson et al., "Protection of Myocardial Function and Coronary Vasculature by Streptokinase," <i>J. Cardiovasc. Pharmacol.</i> 12(2):186-195, 1988.
	Rabkin, "Streptokinase But Not TPA Ameliorates a Cellular Response of Cardiomyocytes To Anoxia and Reoxygenation," <i>Can. J. Cardiol.</i> 7(Suppl. A): p. 80A, Abstract No. 72, 1991.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

11000 U.S. PTO
09/919703
07/31/01